Find a Clinical Trial

Showing 121 - 130 of 251 Trials

Randomized Phase 2 trial of Isatuximab during Autologous Stem Cell Collection and Transplantation Period in patients with Multiple Myeloma and Lymphoma

Principal Investigator:

Divaya Bhutani, MD

Contact Number:

212-342-5162

NCT Number:

NCT05346809

Population:

Adult

Phase:

II

The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant procedures and on the other arm (experimental arm), Participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each Participant will have about 66% chance of getting...
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Principal Investigator:

Jennifer Effie Amengual, MD

Contact Number:

212-342-5162

NCT Number:

NCT05890352

Population:

Adult

Phase:

II

The purpose of this study is to compare the usual treatment alone to using tazemetostat or zanubrutinib plus the usual treatment for patients with relapsed or refractory large b-cell lymphoma (LBCL). Relapsed means the LBCL has returned after it responded to treatment. Refractory means the LBCL did not respond to earlier treatment. The addition of tazemetostat or zanubrutinib to the usual treatment could shrink the cancer or extend your time without cancer symptoms coming back. But it may also cause side effects, which the doctors will monitor. This study will help the study doctors find out...
SHOrt course Radiation and TASOX (TAS102 plus oxaliplatin) chemotherapy in operable rectal cancer, a phase II trial. (Virginia Mason IRB CRP18085)

Principal Investigator:

Lisa Ann Kachnic, MD, FASTRO

Contact Number:

212-342-5162

NCT Number:

NCT04417699

Population:

Adult

Phase:

II

The main purpose of this study is to see if short-course radiation therapy followed by three months of chemotherapy with TAS-102 and oxaliplatin together (known as TASOX) is a safe and effective way to prepare patients for total mesorectal excision (a type of surgery for patients with advanced rectal cancer to remove the tumor and affected areas). Are you Eligible? (Inclusion Criteria) To be considered for this study, subjects should: -be 18 years of age or older -be newly diagnosed with rectal adenocarcinoma and meet other pathological requirements -have no metastatic disease and meet other...
Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients

Principal Investigator:

Nicole Lamanna, MD

Contact Number:

212-342-5162

NCT Number:

NCT04419519

Population:

Adult

Phase:

II

The purpose of this study is to find out whether people who are currently receiving treatment with venetoclax can stop treatment and remain off-treatment for at least 12 months, if they are free of residual disease (MRD- negative) when they stop treatment. Are you Eligible? (Inclusion Criteria) > 18-years-old Diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma confirmed by the enrolling institution Receiving treatment with a venetoclax-based regimen as defined below: - Venetoclax monotherapy (therapy that uses one type of treatment) Venetoclax in combination with anti...
S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Principal Investigator:

Eileen Patricia Connolly, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT03598257

Population:

Adult

Phase:

II

This study is being done to answer the following question: Can we lower the chance of your cancer returning by adding the drug Olaparib to the usual radiation therapy for your cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your inflammatory breast cancer. The usual approach is defined as care most people get for inflammatory breast cancer when they have already received chemotherapy and had surgery to remove the cancer. Are you Eligible? (Inclusion Criteria) To be considered for this trial, subjects must have:...
TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy An open label, multi-cohort, multi-center phase II study evaluatingthe efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma

Principal Investigator:

Larisa J. Geskin, MD

Contact Number:

212-342-5162

NCT Number:

NCT03902184

Population:

Adult

Phase:

II

The purpose of this study is to evaluate the effectiveness and safety of a new experimental drug named IPH4102. IPH4102 is an antibody. Antibodies are proteins which are produced by cells of your immune system, your body’s defense system. They recognize foreign or unwanted material, such as bacteria, viruses or certain surface proteins of lymphoma cells. One part of IPH4102 recognizes and binds a protein called KIR3DL2 on the surface of tumor cells and another part binds to a specific kind of immune cells, called Natural Killer (NK) cells. When the tumor cell and the NK cell are...
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis System as an interventional therapy for the treatment of CTCL (Mycosis Fungoides) in patients with TMN classification stage IA, IB or IIA, an open-label,

Principal Investigator:

Larisa J. Geskin, MD

Contact Number:

212-342-5162

NCT Number:

NCT05680558

Population:

Adult

Phase:

II

To assess the efficacy of the UVAR® THERAKOS® CELLEX Photopheresis System to treat early stage (IA, IB or IIA) cutaneous T-cell lymphoma (CTCL) using the modified skin-weighted assessment tool (mSWAT) to determine overall response. Are you Eligible? (Inclusion Criteria) This study will include patients who have the diagnosis of Mycosis Fungoides (including confirmatory biopsy) and are over the age of 18. Patients must have the appropriate staging (IA, IB or IIA) and be refractory to at least one of the standard therapies used to treat Mycosis Fungoides. Patients must not be on any...
XmAb20717-05: A Phase 2 Study of XmAb®20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT05032040

Population:

Adult

Phase:

II

The purpose of this study is to assess whether an investigational drug, called XmAb20717, has any effects on your cancer, and to determine if it is safe and well tolerated.XmAb20717 is a type of drug that can attach to 2 different proteins, call a bispecific antibody. These antibodies are designed to attach to a T-cell, a type of immune system cell, in your body and ultimately help the body to fight the cancer. An antibody is a special kind of protein that your body normally makes to fight infections and other types of harmful cells and substances in your body. Scientists can now produce...
ZN-c3-005_GOG 3066-DENALI: A PHASE 2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ZN‑c3 IN SUBJECTS WITH HIGH-GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER.

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT05128825

Population:

Adult

Phase:

II

Participants are being invited to take part in a clinical research study because they have been diagnosed with locally advanced or metastatic solid tumors with mutations in the following genes: MRE11, RAD50, NBN or CCNE1 amplification. If the participant takes part in the study, they will take an investigational drug referred to as ZN-c3 (“Study Drug”). ‘Investigational’ means that the Study Drug is currently being tested and has not been approved by the U.S. Food and Drug Administration (FDA) or any other health or regulatory authority in other countries. The purpose...
A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKERADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITHLENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORYFOLLICULAR LYMPHOMA

Principal Investigator:

Jennifer Effie Amengual, MD

Contact Number:

212-342-5162

NCT Number:

NCT04224493

Population:

Adult

Phase:

I/III

The purpose of the study is to evaluate the safety and tolerability of tazemetostat in combination with lenalidomide + rituximab in patients with follicular lymphoma that has returned or has not responded to treatment (relapsed/refractory). The study will also try to select a recommended phase 3 dose of tazemetostat for further evaluation. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Do you have follicular lymphoma? Has your disease relapsed or progressed during/after treatment? Are you able to take oral medication?

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages